Compare WVE & LTGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WVE | LTGO |
|---|---|---|
| Founded | 2012 | N/A |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2015 | 2026 |
| Metric | WVE | LTGO |
|---|---|---|
| Price | $5.06 | $24.45 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 16 | 0 |
| Target Price | ★ $29.81 | N/A |
| AVG Volume (30 Days) | ★ 3.2M | 318.2K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,704,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $85.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 149.43 | N/A |
| 52 Week Low | $5.01 | $17.22 |
| 52 Week High | $21.73 | $25.93 |
| Indicator | WVE | LTGO |
|---|---|---|
| Relative Strength Index (RSI) | 39.27 | 87.86 |
| Support Level | $5.02 | $18.46 |
| Resistance Level | $6.39 | N/A |
| Average True Range (ATR) | 0.31 | 1.46 |
| MACD | -0.01 | 0.58 |
| Stochastic Oscillator | 2.26 | 92.76 |
WAVE Life Sciences Inc is a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines also known as oligonucleotides, targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates, LTG-001 and LTG-321, are oral Nav1.8 inhibitors being developed for the treatment of acute pain. The company is also developing additional Nav1.8 inhibitor candidates using alternative formulations and delivery approaches.